Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003254 · ClinicalTrials.gov registry record · Phase 2
SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00003254 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 75 participants.
The verdict
NCT00003254, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Ethynyluracil may help fluorouracil kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of fluorouracil plus ethynyluracil in treating patients with advanced colorectal cancer that has not responded to fluorouracil.
Interventions
- DRUG fluorouracil
- DRUG ethynyluracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1998-04 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003254
The ClinicalTrials.gov registry entry for NCT00003254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fluorouracil is the first listed.
NCT00003254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003254 about?
NCT00003254 is a clinical study titled "SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Ethynyluracil may help fluorouracil kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of fluorouracil plu...
What is the current status of trial NCT00003254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 1998-04. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00003254?
The interventions under investigation include: fluorouracil (DRUG), ethynyluracil (DRUG).
Who is sponsoring clinical trial NCT00003254?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.